Edwards Lifesciences' PASCAL System Outperforms Medical Therapy in Tricuspid Repair Trial
Bitget2026/11/02 18:25- Edwards Lifesciences’ PASCAL tricuspid repair system outperformed medical therapy alone on the CLASP II TR trial’s six-month primary endpoint.
- Reductions in tricuspid regurgitation and improvements in patient health status persisted through one year, with low adverse event rates at 30 days.
- Results were presented at the Transcatheter Cardiovascular Therapeutics symposium.
- The system received FDA approval for tricuspid valve repair in October 2026, following CE Mark certification in 2020.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
Pendle Bridge integrates with BungeeExchange, supporting cross-chain transfers across 13 networks
Barclays significantly increased holdings in Tesla (TSLA.US) and Intel (INTC.US) in Q3, and bought Nasdaq ETF options for hedging
According to disclosures by the U.S. Securities and Exchange Commission (SEC), Barclays has submitted its third-quarter holdings report (13F) as of September 30, 2026.
Crypto prices
More
